Karyopharm Therapeutics (KPTI) Non Operating Income (2016 - 2025)
Historic Non Operating Income for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to -$84.4 million.
- Karyopharm Therapeutics' Non Operating Income fell 2163596.94% to -$84.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$95.3 million, marking a year-over-year decrease of 32121.5%. This contributed to the annual value of -$105.3 million for FY2025, which is 34441.48% down from last year.
- Per Karyopharm Therapeutics' latest filing, its Non Operating Income stood at -$84.4 million for Q4 2025, which was down 2163596.94% from -$17.9 million recorded in Q3 2025.
- Karyopharm Therapeutics' Non Operating Income's 5-year high stood at $52.0 million during Q2 2024, with a 5-year trough of -$84.4 million in Q4 2025.
- Over the past 5 years, Karyopharm Therapeutics' median Non Operating Income value was -$4.7 million (recorded in 2021), while the average stood at -$5.7 million.
- In the last 5 years, Karyopharm Therapeutics' Non Operating Income surged by 187402.73% in 2024 and then plummeted by 2163596.94% in 2025.
- Karyopharm Therapeutics' Non Operating Income (Quarter) stood at -$8.4 million in 2021, then soared by 45.43% to -$4.6 million in 2022, then increased by 14.57% to -$3.9 million in 2023, then surged by 110.05% to $392000.0 in 2024, then plummeted by 21635.97% to -$84.4 million in 2025.
- Its Non Operating Income stands at -$84.4 million for Q4 2025, versus -$17.9 million for Q3 2025 and -$12.8 million for Q2 2025.